Advances in Psoriasis: A Multisystemic Guide
Editat de Jeffrey M. Weinberg, Mark Lebwohlen Limba Engleză Paperback – 17 sep 2016
Toate formatele și edițiile | Preț | Express |
---|---|---|
Paperback (2) | 566.29 lei 38-44 zile | |
Springer International Publishing – 27 noi 2021 | 566.29 lei 38-44 zile | |
SPRINGER LONDON – 17 sep 2016 | 1011.84 lei 6-8 săpt. | |
Hardback (1) | 853.29 lei 3-5 săpt. | |
Springer International Publishing – 27 noi 2020 | 853.29 lei 3-5 săpt. |
Preț: 1011.84 lei
Preț vechi: 1065.10 lei
-5% Nou
Puncte Express: 1518
Preț estimativ în valută:
193.63€ • 204.17$ • 161.19£
193.63€ • 204.17$ • 161.19£
Carte tipărită la comandă
Livrare economică 11-25 ianuarie 25
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9781447169178
ISBN-10: 1447169174
Pagini: 332
Ilustrații: XVIII, 332 p. 55 illus., 45 illus. in color.
Dimensiuni: 178 x 254 mm
Greutate: 0.61 kg
Ediția:Softcover reprint of the original 1st ed. 2014
Editura: SPRINGER LONDON
Colecția Springer
Locul publicării:London, United Kingdom
ISBN-10: 1447169174
Pagini: 332
Ilustrații: XVIII, 332 p. 55 illus., 45 illus. in color.
Dimensiuni: 178 x 254 mm
Greutate: 0.61 kg
Ediția:Softcover reprint of the original 1st ed. 2014
Editura: SPRINGER LONDON
Colecția Springer
Locul publicării:London, United Kingdom
Cuprins
Introduction to Psoriasis and Psoriasis Therapy.- Pathophysiology of Psoriasis/Novel Pathways.- Psoriasis and Psoriasis Arthritis: Clinical Review and Update.- Overview of Therapeutic Options/Pharmacology.- Topical Therapy.- Ultraviolet and Laser Therapy.- Traditional Systemic Therapy.- Biologics I: TNF Inhibitors.- Biologics II: IL-12/23 and T-Cell Targeted Therapy.- Research Pipeline I: Topicals and Oral Therapies.- Research Pipeline II: Biologic Therapies.- Summary of Published Treatment Guidelines.- Reimbursement Issues/Aides.- Patient Support Programs and Organizations.- Conclusion.- Appendix: Directory of Helpful Websites/Online Resources/Telephone Numbers.
Textul de pe ultima copertă
The understanding and management of psoriasis have evolved dramatically over the last decades and, as a result, guidelines and treatment options have changed dramatically. To meet the need for a up-to-date practical resource in this area, the Editors have brought together a team of experts in the field to produce a highly informative and illustrated guide to the decision-making process for psoriasis.
Advances in Psoriasis: A Multisystemic Guide provides physicians with a reference on the disease and its comorbidities and therapeutic options. It will help physicians further their knowledge of the science and therapy of psoriasis. As well as practicing dermatologists, fellows in dermatology will find this book to be an essential training resource to learn about the treatment and management of psoriasis.
Advances in Psoriasis: A Multisystemic Guide provides physicians with a reference on the disease and its comorbidities and therapeutic options. It will help physicians further their knowledge of the science and therapy of psoriasis. As well as practicing dermatologists, fellows in dermatology will find this book to be an essential training resource to learn about the treatment and management of psoriasis.
Caracteristici
Copious illustrations with emphasis on practical clinical knowledge Up-to-date clinical reference on the topic Bench-to-bedside approach
Notă biografică
Dr. Weinberg, is an Associate Clinical Professor of Dermatology at Mount Sinai School of Medicine, New York. In addition, he is director of the Clinical Research Center/Dermatopharmacology at St. Luke’s-Roosevelt Hospital Center and acting director of the Division of Dermatology at Jamaica Hospital Medical Center, both in New York City. Prior to this he was an Assistant Clinical Professor of Dermatology at Columbia University College of Physicians and Surgeons in New York City. Dr. Weinberg graduated from the University of Pennsylvania School of Medicine in Philadelphia and completed an internship in medicine at Columbia-Presbyterian Medical Center in New York City. He then completed a residency in dermatology at the University of Pennsylvania School of Medicine. He is a fellow of the American Academy of Dermatology, where he has served on several committees, and a member of the Dermatology Foundation. He is a diplomat of the American Board of Dermatology.
Dr. Lebwohl graduated from Columbia University in 1974. He earned his medical degree from Harvard Medical School in 1978 and subsequently completed residencies in both internal medicine and dermatology at the Icahn School of Medicine at Mount Sinai. In 1983, he was made Assistant Professor of Dermatology at Mount Sinai. In 1997, he was named Chairman of the Department which, under his leadership, has been at the forefront of the management of psoriasis. He was the first to report the cardiac complications of pseudoxanthoma elasticum, and, additionally, he has developed new techniques for diagnosing the disease. He was also the first to use immunomodulators (imiquimod) to treat preccancerous skin lesions, the first to use topical calcineurin inhibitors to treat psoriasis, and the first to identify interactions between topical vitamin D analogues such as calcipotriol and calcitriol with other topical medications and with ultraviolet light. He has been at the forefront of clinical trials for new biologic therapies for psoriasis.
Dr. Lebwohl graduated from Columbia University in 1974. He earned his medical degree from Harvard Medical School in 1978 and subsequently completed residencies in both internal medicine and dermatology at the Icahn School of Medicine at Mount Sinai. In 1983, he was made Assistant Professor of Dermatology at Mount Sinai. In 1997, he was named Chairman of the Department which, under his leadership, has been at the forefront of the management of psoriasis. He was the first to report the cardiac complications of pseudoxanthoma elasticum, and, additionally, he has developed new techniques for diagnosing the disease. He was also the first to use immunomodulators (imiquimod) to treat preccancerous skin lesions, the first to use topical calcineurin inhibitors to treat psoriasis, and the first to identify interactions between topical vitamin D analogues such as calcipotriol and calcitriol with other topical medications and with ultraviolet light. He has been at the forefront of clinical trials for new biologic therapies for psoriasis.